Levofloxacin Use in Streptococcal Infections

Clinical Recommendations

The IDSA strongly recommends against fluoroquinolones for streptococcal pharyngitis, as older fluoroquinolones have limited activity and newer ones are expensive with unnecessarily broad spectrum 1, 2
For necrotizing fasciitis caused by Group A Streptococcus, the combination of clindamycin plus penicillin is the recommended treatment, and fluoroquinolones are not part of recommended regimens 3, 4
The Infectious Diseases Society of America recommends levofloxacin for community-acquired pneumonia in adults with comorbidities or recent antibiotic exposure, but it should be reserved for specific clinical scenarios involving streptococci 5, 6

Fluoroquinolone resistance in streptococci is increasing, with S. pneumoniae resistance to ciprofloxacin increasing from 0.3% to 3% in the United States between 1997-1998 and 1999-2000 7
Macrolide resistance among Group A Streptococcus is <5% in the US, with even lower clindamycin resistance 3

The American Academy of Pediatrics and other guidelines suggest that levofloxacin should be used for documented multi-drug resistant S. pneumoniae infections, but not as a first-line agent for streptococcal infections due to its broad spectrum and the need to preserve fluoroquinolone effectiveness 5, 6

Levofloxacin achieves MIC values of approximately 1.0 mg/dL for pneumococci, making it more active than ciprofloxacin but less active than newer fluoroquinolones like moxifloxacin or gatifloxacin 8
Levofloxacin's broad-spectrum activity includes gram-positive, gram-negative, and atypical pathogens, with specific activity against viridans group streptococci 9

Clindamycin provides excellent streptococcal coverage and is active against both alpha- and beta-hemolytic streptococci 10
Institutions using fluoroquinolone prophylaxis must closely monitor local resistance patterns over time 9

Consider levofloxacin for community-acquired pneumonia in adults with comorbidities or recent antibiotic exposure where S. pneumoniae is suspected 8, 9
Levofloxacin prophylaxis reduces bacteremia risk from viridans group streptococci in severe neutropenia in pediatric cancer patients 9
Avoid empiric use of levofloxacin without considering local resistance patterns, as understanding your institution's antibiogram is critical before selecting levofloxacin 9